A Protein Kinase B inhibitor will be taken into clinical development by AstraZeneca, following a successful collaboration with the biotechnology company Astex Therapeutics.
The PKB programme, from which the clinical candidate was selected, stemmed from collaborative research originally carried out by The Institute of Cancer Research, CRT and Astex.
Work with us to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines.
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.
iOnctura SA announces the first patient has been dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.
